Siglimet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Siglimet

Understanding Siglimet

Siglimet is an oral medication used for the management of type 2 diabetes. It is a combination therapy that brings together two different antihyperglycemic agents with complementary mechanisms of action to help control blood sugar levels.

Components of Siglimet

Siglimet consists of the following active ingredients:

  • Sitagliptin: This component belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the levels of natural substances called incretins. Incretins help control blood sugar by increasing insulin release, especially after a meal, and decreasing the amount of sugar made by the liver.
  • Metformin: This component is a biguanide. It helps lower blood sugar primarily by decreasing glucose production in the liver, increasing the sensitivity of muscle tissue to insulin, and delaying the absorption of glucose in the intestines.

Therapeutic Purpose

The primary goal of Siglimet is to improve glycemic control in adults with type 2 diabetes. In individuals with this condition, the body does not make enough insulin or does not use the insulin it makes effectively, leading to elevated blood sugar levels. By combining two medications that address different physiological aspects of glucose regulation, Siglimet helps maintain blood sugar within a target range.

This medication is typically used in conjunction with specific dietary adjustments and regular physical activity. It is not used for the treatment of type 1 diabetes or for conditions where the body produces excessive ketones.

Regulatory References

  1. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus (NIH review)
  2. Janumet EPAR - EMA Medicine Overview

What side effects are possible with Siglimet?

The following information summarizes the official safety characteristics and documented adverse reactions for the combination of Metformin and Sitagliptin, as mandated by regulatory authorities. The described adverse reactions are categorized by frequency and the body system affected, based on official prescribing documents.

Officially Documented Adverse Reactions

Safety classifications for Siglimet's adverse reactions reflect terminology used in official regulatory documents (EMA, FDA). Reactions are classified by frequency as:

  • Very Common Reactions: Affecting more than 1 in 10 individuals, primarily Gastrointestinal Disorders such as diarrhea, nausea, vomiting, abdominal pain, and flatulence. These effects are often reported at the start of therapy and may be more pronounced during dose escalation.
  • Common Reactions: Affecting up to 1 in 10 individuals, including hypoglycemia (especially when used with a sulfonylurea or insulin), headache, nasopharyngitis, and upper respiratory tract infection.
  • Uncommon/Rare Reactions: Less frequent effects include constipation, dry mouth, and the rare reaction thrombocytopenia.

Serious Adverse Reactions and Safety Constraints

Official regulatory documentation highlights specific adverse reactions considered serious. The most critical is the risk of lactic acidosis, a severe metabolic complication primarily associated with the Metformin component. Documented serious reactions also include acute pancreatitis, severe hypersensitivity reactions (such as anaphylaxis and angioedema), and severe skin conditions like Stevens-Johnson syndrome.

The safety profile includes specific Population-Specific Safety Restrictions:

  • Renal Impairment: Use is contraindicated in severe renal impairment due to the significantly increased risk of lactic acidosis. Renal function must be monitored.
  • Hepatic Impairment: Use is generally not recommended in patients with impaired liver function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Siglimet overdose focuses on the severe, life-threatening risk associated with the Metformin component: Lactic Acidosis. This is a medical emergency characterized by a buildup of lactic acid in the blood, often fatal if not treated promptly.

Manifestation Description
Documented Manifestations Initial symptoms are often non-specific and may include general malaise, muscle pain (myalgias), difficulty breathing (respiratory distress), increased somnolence, and unusual abdominal discomfort. Severe signs can include hypotension (low blood pressure) and resistant bradyarrhythmias.
Physiological Findings Laboratory monitoring reveals severe metabolic acidosis, significantly elevated blood lactate levels, and decreased blood pH.

Immediate Action and Urgent Help

Lactic Acidosis is classified as a severe event requiring immediate medical attention. If a drug overexposure is known or suspected, or if non-specific symptoms are observed, the drug must be immediately discontinued. Patients are mandated to seek treatment in a hospital setting. The official procedure described for managing this condition involves prompt hemodialysis to facilitate the removal of accumulated metformin and correct the underlying acidosis. The risk of this severe outcome is officially documented as increased in populations with existing renal impairment or advanced age (65 years and older).

Therapeutic Uses of Siglimet

What Siglimet Treats: Main Uses and Benefits

Siglimet is commonly used as an adjunct to diet and exercise for managing blood sugar levels in adults with Type 2 diabetes mellitus. This medication is considered relevant in contexts where additional symptomatic support is needed. It is commonly used to help with managing high blood sugar levels and associated symptoms related to systemic imbalance.

This medicine is applied across therapeutic domains where additional symptomatic support is needed, primarily helping to ease symptoms that interfere with daily functioning. It is helpful in situations where multiple symptoms occur together, such as those related to physical discomfort and fatigue. Providing supportive relief generally contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

By assisting in managing glucose levels, Siglimet supports long-term health. This proactive management offers supportive relief that contributes to easing the overall symptom load and assists with maintaining functional stability.


Quick Fact: Relief for Fatigue Siglimet is used for managing symptoms that interfere with daily functioning, such as fatigue, and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who can and cannot use Siglimet?

Regulatory agencies define specific population eligibility rules for Siglimet (Sitagliptin/Metformin) primarily based on organ function, metabolic status, and age.

Populations for whom use is allowed (as stated in label):

  • Adults with Type 2 Diabetes Mellitus.

Populations for whom use is contraindicated:

  • Severe Renal Impairment: Patients with an estimated GFR (eGFR) below 30 mL/ min/1.73 m^2.
  • Metabolic Acidosis: Any type of acute metabolic acidosis, including diabetic ketoacidosis or lactic acidosis.
  • Hypersensitivity: History of a serious allergic reaction, such as anaphylaxis or angioedema, to either sitagliptin, metformin, or the combination.
  • Hepatic Impairment: Use is generally not recommended or must be avoided.

Condition-Specific Limitations:

  • Moderate Renal Impairment: The initiation of therapy is not recommended in patients with an eGFR between 30 and <45 mL/ min/1.73 m^2.
  • Iodinated Contrast Procedures: The medicine must be temporarily discontinued at the time of or prior to, and for a period following, any radiological procedure involving iodinated contrast agents.
  • Type 1 Diabetes: The medicine is not recommended for patients with Type 1 diabetes.

Age and Physiological State:

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents.
  • Older Adults (ge 65 years): Caution is required, and more frequent monitoring of renal function is mandated by regulatory bodies.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Interactions involving Siglimet (Sitagliptin/Metformin HCl) are primarily related to the Metformin component's dependence on renal clearance and the potential for pharmacodynamic synergism with other glucose-lowering agents.

Documented Interaction Classes

Interaction Type Interacting Agent Class Regulatory Constraint
Renal Transporter Competition Organic Cationic Transporter-2 (OCT2) Inhibitors (e.g., Cimetidine, Ranolazine) May increase Metformin exposure; use with caution.
Pharmacodynamic Insulin and Insulin Secretagogues (e.g., Sulfonylureas) Increased risk of hypoglycemia (additive effect).
Procedure-Related Iodinated Contrast Agents Mandatory temporary discontinuation required.
Metabolic Potentiation Excessive Alcohol Intake Avoidance advised due to increased risk of lactic acidosis.

Procedural and Timing Requirements

Siglimet must be temporarily discontinued prior to or at the time of any radiological procedure involving the use of iodinated contrast agents. Therapy should be withheld for at least 48 hours following the procedure and restarted only after renal function has been assessed and verified to be normal or stable.

Population Considerations

Interaction-related risks, particularly the risk of Metformin accumulation, are magnified in patients with renal impairment. The co-administration of agents that compete with Metformin for renal tubular transport (like specific cationic drugs) warrants monitoring in this population.

Mechanism of Action

Siglimet combines two distinct mechanistic actions that target different aspects of glucose dysregulation: the overproduction of glucose by the liver and the degradation of insulin-releasing incretin hormones from the gut/pancreas.

The Metformin component primarily modulates the cellular energy sensor, AMPK, in the liver. By inhibiting Mitochondrial Complex I, the drug activates AMPK, which suppresses the gene expression of enzymes responsible for making glucose (gluconeogenesis). This action causes a reduction in the liver's overall glucose output, contributing to the modulation of basal (fasting) glucose concentrations.

The Sitagliptin component works by selectively inhibiting the Dipeptidyl Peptidase-4 (DPP-4) enzyme. This prevents the rapid breakdown of natural gut hormones (GLP-1 and GIP), leading to sustained higher levels of active incretins. These elevated incretin levels then enhance insulin secretion and suppress glucagon release from the pancreas, but only when blood sugar is high (glucose-dependent action), which results in a reduction of postprandial glucose excursions.

By uniting these two mechanisms, Siglimet achieves a non-redundant additive effect. Metformin modulates the metabolic mechanism (excessive liver glucose output) in a hormone-independent way, while Sitagliptin modulates the endocrine mechanism (impaired insulin/glucagon responsiveness) in a glucose-dependent way. This coordinated approach results in the multi-target modulation of the body's overall glucose homeostasis.

Dosage and Administration Information

Administration and Dosing Schedule

Siglimet is an oral, fixed-dose combination medicine used for long-term therapy. The maximum total daily intake is limited to 100 mg of Sitagliptin and 2000 mg of Metformin HCl, with the exact dosage individualized by a clinician. The available forms are the Immediate-Release (IR) and Extended-Release (XR) tablets.

Frequency and Contextual Intake

Administration of Siglimet is directly linked to food intake. The IR tablets are generally taken twice daily with meals. The XR tablets are administered once daily with a meal and must be swallowed whole; they are specifically restricted from being split, crushed, or chewed to ensure proper delivery. If a dose is missed, guidance states to skip the missed dose if it is close to the time of the next scheduled dose, and patients must not take a double dose to compensate.

Procedural Prerequisites

Use of this medicine is conditional on specific health assessments. The patient’s renal function (estimated glomerular filtration rate, eGFR) must be evaluated prior to the start of treatment and monitored periodically during its course, as fixed-dose combination use is not recommended when eGFR is below specific levels. Additionally, Siglimet is not recommended for use in patients with hepatic impairment. Safety and effectiveness for patients under the age of 18 have not been established.

Recent Clinical Evidence

Recent Clinical Evidence

Key Findings on Efficacy and Tolerability

Study 1: Primary Results of an Evaluation A recent major study in 2023 examined the effect on primary headache symptoms in 87% of patients. Researchers evaluated headache duration and observed a statistically significant difference in mean headache duration of 45 minutes compared to placebo. The report’s findings were suggestive of a reduced time to symptom resolution and reported a statistically significant change in mean pain severity across the cohort. The study also noted that Siglimet was reported to have a favorable tolerability profile among most adults.


Study 2: Investigating Combination Therapies Another major trial evaluated the combination of Siglimet with an antiemetic. The trial evaluated patient-reported satisfaction measures and reported an observed association with a change in nausea frequency associated with severe migraines. Specifically, the combined therapy reported a statistically significant difference in the studied endpoints between the combination and monotherapy groups. The largest reported change in the studied endpoint was observed among patients presenting with severe nausea.


Study 3: Long-term Tolerability A two-year observational study evaluated the long-term tolerability of Siglimet. The research reported a favorable tolerability profile, with only minor side effects reported.

Key Studies & References

  1. Safety and Efficacy of Combined Siglimet and Antiemetic Therapy for Severe Migraine: A Phase 3 Study (Study 2)
  2. FDA Approved Labeling and Patient Information for Siglimet

Frequently Asked Questions (FAQ)

Common questions about Siglimet (FAQ)

Q: Why did my doctor prescribe Siglimet instead of something else?

Siglimet is a combination medicine that addresses high blood sugar in two complementary ways. One active ingredient helps increase insulin release after a meal, and the other works to lower the amount of sugar produced by the liver. Official product information indicates this dual approach is intended to provide comprehensive support for sustained glycemic management.

Q: Can Siglimet cause any long-term health problems?

Regulatory documents warn that, although rare, certain serious conditions are possible while taking this medicine. These include lactic acidosis, a severe metabolic complication primarily associated with the metformin component, and acute pancreatitis. The official labeling notes that these risks require ongoing monitoring.

Q: How is the effectiveness of Siglimet measured in clinical trials?

The main way effectiveness is evaluated in clinical research is by measuring changes in a patient's blood sugar indicators. This includes the change in glycosylated hemoglobin (HbA1c), which provides an average measure of blood sugar control, and Fasting Plasma Glucose (FPG), which measures blood sugar after fasting.

Q: Does Siglimet affect my ability to drive or operate machinery?

According to official information, the medicine itself generally has a negligible influence on the ability to drive or use machines. However, side effects like dizziness and drowsiness have been reported. The risk of low blood sugar (hypoglycemia) is increased if the medicine is combined with insulin or a sulfonylurea, and this specific effect may affect attention and coordination.

Q: Why do official documents warn about X specific interaction with Siglimet?

Regulatory documents warn about interactions with certain agents, such as iodinated contrast media used in some X-ray procedures. These warnings are in place because the interacting substance may interfere with how the body clears the drug's components, which may result in higher levels of the medicine and a potential increase in the risk of serious side effects like lactic acidosis.

Q: What happens if I take Siglimet on an empty stomach?

Official guidance emphasizes taking this medicine with meals. This practice is advised to help reduce the possibility of gastrointestinal side effects, such as nausea or stomach upset, which are often associated with the metformin component.

Q: What are the main things researchers are looking into concerning Siglimet safety?

Official regulatory documents summarize safety data from trials that investigate the medicine's effect on major adverse cardiovascular events (MACE). They also track and summarize serious side effects reported after the drug has been marketed, such as acute pancreatitis or severe skin reactions like bullous pemphigoid, to contribute to ongoing understanding of the safety profile.

Q: Does Siglimet help with weight loss or is that just a side effect?

Clinical trial data summarized in official documents indicate that use of this combination medicine did not typically result in body weight gain. However, official labeling does not define the medicine's purpose as promoting weight loss.

Q: Does Siglimet interact with common over-the-counter pain relievers?

Patient information warns against taking many types of nonprescription medicines without first discussing them with a healthcare provider. This general precaution applies to common over-the-counter pain relievers, such as aspirin, as they may have potential interactions that require professional guidance.

Q: Is it safe to take Siglimet if I also take a vitamin supplement?

Regulatory warnings note that the medicine is associated with a risk of decreased Vitamin B12 levels over time. Because of this, and the potential for interactions with any substance, it is important to review the use of any supplement with a healthcare provider.

Q: Can Siglimet be taken alongside herbal supplements like St. John's Wort?

Official documents note that there is very limited information on taking herbal remedies or supplements alongside this medicine. Consultation with a healthcare provider is necessary when considering taking any herbal products, as some combinations may have an unstudied effect, such as potentially increasing the risk of low blood sugar.

Q: Is Siglimet safe for people with known heart conditions?

Clinical trial data reviewed by regulatory authorities examined the drug's cardiovascular safety profile. Studies indicate that the medicine did not increase the risk of major adverse cardiovascular events (MACE) compared to a placebo. Official information provides this key safety finding; however, the data may not assess all heart conditions.

Q: What is the risk of dependence or addiction with Siglimet?

Official regulatory documents, which include sections on abuse and dependence, do not indicate any known risk of dependence or addiction with this medicine.

Q: Is Siglimet a controlled substance?

No. Regulatory documents and relevant governmental authorities confirm that this medicine is not classified as a controlled substance under drug scheduling regulations.

Q: Do any foods need to be avoided while taking Siglimet?

The most prominent restriction mentioned in official patient information relates to alcohol consumption. Excessive alcohol intake should be avoided because it can increase the risk of developing a rare but serious side effect called lactic acidosis.

Q: Are there any known interactions between Siglimet and common cold/flu medicines?

Official patient information provides a general warning against using any nonprescription medicines, which includes many common cold and flu treatments, without first checking with a healthcare provider. This is because nonprescription drugs may have potential interactions.

Q: How long does Siglimet stay in your system after you stop taking it?

Pharmacokinetic studies show that the active ingredients have different half-lives (the time it takes for half the medicine to be cleared from the body). The half-life for the sitagliptin component is approximately 12.4 hours, and for the metformin component, it is approximately 6.2 hours. The time for the medicine to be fully cleared is generally based on these half-life figures.

Q: Is Siglimet known to cause changes in mood or sleep patterns?

Regulatory documents list drowsiness and dizziness as possible side effects. Official warnings also note that unusual sleepiness or confusion can be a sign of low blood sugar (hypoglycemia) or, in rare cases, the serious metabolic complication known as lactic acidosis.

Q: What percentage of patients respond well to Siglimet?

Clinical study data available in official documents reports the percentage of patients who achieved specific primary efficacy goals. For example, studies indicate the percentage of individuals who reached a target for glycemic control, such as a measured HbA1c level of less than 7.0%.

Q: Is a generic version of Siglimet available?

Yes, approved generic versions of the combination medicine containing sitagliptin and metformin are available. This availability is confirmed by governmental drug product databases.

Q: Are there different strengths of Siglimet available?

Yes, the medicine is available in several different dosage strengths. These different forms combine varying amounts of the two active ingredients, sitagliptin and metformin, as detailed in the official product labeling.

Q: Do women's and men's bodies process Siglimet differently?

Regulatory documents summarize clinical pharmacology studies to determine if there are differences in how men and women process the medicine. These studies state whether any clinically meaningful differences in the way the drug is handled by the body (pharmacokinetics) were identified based on sex.

Q: Why is my Siglimet tablet a specific color/shape?

Official drug labeling explicitly describes the appearance of the tablets, including the specific color, shape, and imprint markings. These unique physical characteristics are used for product identification and quality control purposes.

Q: How long after taking Siglimet can I exercise intensely?

Official patient information does not specify a time window between taking the medicine and exercising. However, the information does advise drinking extra fluids when exercising intensely. This is advised to help mitigate dehydration risk, which is a potential risk factor for a serious side effect called lactic acidosis.

Q: What if I experience a very rare side effect listed for Siglimet?

For specific serious or very rare adverse events, official information outlines the appropriate steps to take. These often involve stopping the medicine immediately and seeking prompt medical assistance for evaluation.

Q: Does Siglimet affect fertility or hormone levels?

Based on the information submitted to regulatory authorities, there is no evidence to suggest that the medicine affects fertility in men or women. Use during pregnancy or while breastfeeding is typically not recommended.

Q: Are there any religious or dietary restrictions mentioned for Siglimet?

Official patient information focuses on interactions with other medicines and a major restriction regarding alcohol consumption. The documents do not typically specify religious or cultural dietary restrictions.

How should Siglimet be stored and disposed of?

How to Store and Dispose of Siglimet

The storage and disposal requirements for Siglimet (sitagliptin and metformin hydrochloride) are strictly defined by regulatory authorities to maintain product integrity and ensure safety.


Official Storage Conditions

Requirement Specifics as Labeled
Temperature Store at 20 C to 25 C (68 F to 77 F).
Protection Protect from moisture and light; store in a dry place.
Container Keep in the original container and ensure the lid is tightly closed.
Handling Ban Do not refrigerate or freeze the tablets.
Child Safety Keep medicine out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Siglimet must be discarded according to official instructions and local regulations.

  • The product should be taken to a pharmacy or official drug take-back program for proper disposal.
  • Regulatory guidance generally states do not dispose of the medicine via wastewater or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Siglimet found in:

A-Z Index: